| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | VP24 |
| Uniprot No | Q4KRW3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-194aa |
| 氨基酸序列 | SRRNPCKFEIRGHCLNGKRCHFSHNYFEWPPHALLVRQNFMLNRILKSMDKSIDTLSEISGAAELDRTEEYALGVVGVLESYIGSINNITKQSACVAMSKLLTELNSDDIKKLRDNEELNSPKIRVYNTVISYIESNRKNNKQTIHLLKRLPADVLKKTIKNTLDIHKSITINNPKELTVSDTNDHAKNNDTT |
| 预测分子量 | 51.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于埃博拉病毒VP24重组蛋白的代表性文献摘要(文献标题及内容为模拟生成，建议通过PubMed等数据库核实具体信息)：
---
1. **标题**: *Structural basis of Ebola virus VP24-mediated immune evasion*
**作者**: Leung DW et al.
**摘要**: 解析埃博拉病毒VP24重组蛋白的晶体结构，揭示其通过结合宿主核转运蛋白(如karyopherin α)抑制STAT1核转运，从而阻断干扰素信号通路的分子机制。
---
2. **标题**: *Ebola virus VP24 protein production and purification for antibody generation*
**作者**: Xu W et al.
**摘要**: 报道利用大肠杆菌表达系统高效表达重组VP24蛋白，通过His标签亲和层析纯化，并验证其作为抗原用于动物免疫以产生特异性抗体的可行性。
---
3. **标题**: *VP24 phosphorylation modulates its interaction with host proteins*
**作者**: Zhang Y et al.
**摘要**: 研究重组VP24蛋白的磷酸化修饰对其功能的影响，发现特定磷酸化位点突变可削弱VP24与宿主蛋白的结合能力，进而影响病毒复制效率。
---
4. **标题**: *Functional analysis of VP24 in Ebola virus assembly*
**作者**: Watanabe S et al.
**摘要**: 通过重组VP24蛋白与病毒核衣壳蛋白NP的体外结合实验，证实VP24在病毒粒子组装过程中的关键作用，并鉴定其关键相互作用结构域。
---
**建议**：通过PubMed搜索关键词 *"Ebola VP24 recombinant"* 或结合DOI查询具体文献。部分经典研究可参考：
- *Nature* (2014) 论文：揭示VP24抑制干扰素信号通路机制
- *Cell Host Microbe* (2015) 论文：VP24结构解析与宿主靶点
**Background of VP24 Recombinant Protein**
The VP24 recombinant protein is derived from the Ebola virus (EBOV), a member of the *Filoviridae* family responsible for severe hemorrhagic fever in humans. VP24 is a multifunctional structural protein encoded by the EBOV genome, playing critical roles in viral pathogenesis and immune evasion. Unlike other viral proteins, VP24 is not directly involved in replication but serves as a minor matrix protein, contributing to viral assembly and nucleocapsid formation. Its primary significance lies in its ability to subvert host innate immune responses, particularly by inhibiting interferon (IFN) signaling—a key antiviral defense mechanism.
VP24 achieves immune suppression by blocking the nuclear import of transcription factors like STAT1. essential for IFN-stimulated gene expression. This interaction occurs through VP24's binding to host karyopherin proteins (e.g., KPNA), disrupting STAT1 nuclear translocation. Structural studies reveal VP24's unique fold, featuring a conserved hydrophobic core and surface regions critical for host protein interactions. Such insights have made VP24 a focal point for studying EBOV-host interactions and developing targeted therapies.
Recombinant VP24 is produced via heterologous expression systems (e.g., *E. coli* or mammalian cells), enabling scalable purification for research and diagnostic applications. It serves as a vital tool for elucidating EBOV pathogenesis, screening antiviral compounds, and developing serological assays. Recent efforts also explore its potential in vaccines or as a component of subunit-based therapeutics. Despite progress, challenges remain in fully understanding its pleiotropic roles and leveraging its structure for drug design. Ongoing research aims to decode its interactions with other viral proteins (e.g., VP35) and host pathways, offering hope for novel interventions against Ebola and related filoviruses.
×
